Our Blog

 

Mechanisms Responsible for the Benefit on Cardiovascular Risk in the REDUCE-IT Trial

By Kevin Maki PhD | Oct 12, 2018 | 0 Comments

Mechanisms Responsible for the Benefit on Cardiovascular Risk in the REDUCE-IT Trial By Kevin C Maki, PhD   Recently, we learned of the impressive topline results from the Reduction of Cardiovascular Events with Eicosapentaenoic Acid (EPA) – Intervention Trial (REDUCE-IT), which showed that Vascepa® (icosapent ethyl or EPA ethyl esters) lowered major adverse cardiovascular events…

Read More

Meta-regression Characterizes the Relationships Between Changes in Dietary Cholesterol Intake and Plasma Low-density and High-density Lipoprotein Cholesterol Changes

By Kevin Maki PhD | Oct 11, 2018 | 0 Comments

Meta-regression Characterizes the Relationships Between Changes in Dietary Cholesterol Intake and Plasma Low-density and High-density Lipoprotein Cholesterol Changes By Kevin C Maki, PhD and Orsolya M Palacios, PhD   Our group recently collaborated with scientists from the University of Cincinnati to conduct meta-regression analyses that investigated the dose-response relationships between changes in dietary cholesterol intake…

Read More

Topline Results from REDUCE-IT Show a Significant Reduction in Cardiovascular Outcomes with Omega-3 Fatty Acid

By Kevin Maki PhD | Oct 11, 2018 | 0 Comments

Topline Results from REDUCE-IT Show a Significant Reduction in Cardiovascular Outcomes with Omega-3 Fatty Acid By Kevin C Maki, PhD and Mary R Dicklin, PhD   Exciting topline results from the Reduction of Cardiovascular Events with Eicosapentaenoic Acid (EPA) – Intervention Trial (REDUCE-IT) were recently announced by Amarin, the maker of Vascepa®.1 The full results…

Read More

Results from A Study of Cardiovascular Events in Diabetes (ASCEND): Taking a Closer Look at the Potential Benefit of Omega-3 Fatty Acids for Preventing Cardiac Death

By Kevin Maki PhD | Sep 13, 2018 | 0 Comments

Results from A Study of Cardiovascular Events in Diabetes (ASCEND): Taking a Closer Look at the Potential Benefit of Omega-3 Fatty Acids for Preventing Cardiac Death By Kevin C Maki, PhD; Mary R Dicklin, PhD   Results from A Study of Cardiovascular Events in Diabetes (ASCEND) were recently presented at the European Society of Cardiology…

Read More

A Review of Three Recently Published Papers on Dietary Approaches to Weight Loss and Fat Mobilization

By Kristen N Smith PhD RDN Mary R Dicklin PhD Kevin Maki PhD | May 24, 2018 | 0 Comments

A Review of Three Recently Published Papers on Dietary Approaches to Weight Loss and Fat Mobilization By Kristen N Smith, PhD, RD; Mary R Dicklin, PhD; Kevin C Maki, PhD, CLS   Background: There have been multiple papers published this year focusing on various dietary approaches for producing weight loss and their effects on weight-related…

Read More

Participants with Elevated Lp (a) Had Greater than Average Benefit from Evolocumab in FOURIER

By Kevin Maki PhD | May 17, 2018 | 0 Comments

Participants with Elevated Lp (a) Had Greater than Average Benefit from Evolocumab in FOURIER Kevin C Maki, PhD, CLS, FNLA and Mary R Dicklin, PhD It has been known for decades that an elevated level of lipoprotein (a) or Lp (a) is associated with increased cardiovascular disease (CVD) risk.  The Lp (a) particle consists of…

Read More

Differential Effects of n-3 and n-6 Fatty Acids on Carotid Plaque and Its Progression: Analyses from The Multi-Ethnic Study of Atherosclerosis

By Kristen N Smith PhD RDN Mary R Dicklin PhD Kevin Maki PhD | Apr 1, 2018 | 0 Comments

Differential Effects of n-3 and n-6 Fatty Acids on Carotid Plaque and Its Progression: Analyses from The Multi-Ethnic Study of Atherosclerosis By Kristen N Smith, PhD, RD, LD; Mary R Dicklin, PhD; Kevin C Maki, PhD, CLS, FNLA  Background: The process of atherosclerotic development is multifactorial involving inflammation, endothelial activation, oxidative stress and lipid accumulation…

Read More

ODYSSEY Outcomes Trial: Topline Results and Clinical Implications

By Kevin Maki PhD | Mar 26, 2018 | 0 Comments

ODYSSEY Outcomes Trial: Topline Results and Clinical Implications By Kevin C Maki, PhD, CLS, FNLA; Kristen N Smith, PhD, RD, LD; Mary R Dicklin, PhD  Background: Cardiovascular disease (CVD) event risk is high in those with recent acute coronary syndromes (ACS), despite treatment with evidence-based preventive therapies. Prior research has shown that CVD event risk…

Read More

24-Hour Urinary Collection Data Support Strong Associations between Sodium and Potassium Excretion and Blood Pressure in the National Health and Nutrition Examination Survey

By Kristen N Smith PhD RDN Mary R Dicklin PhD Kevin Maki PhD | Mar 5, 2018 | 0 Comments

24-Hour Urinary Collection Data Support Strong Associations between Sodium and Potassium Excretion and Blood Pressure in the National Health and Nutrition Examination Survey By Kristen N Smith, PhD, RD, LD; Mary R Dicklin, PhD; Kevin C Maki, PhD  Background: It is well established that hypertension is an important modifiable risk factor for cardiovascular disease (CVD),…

Read More

Summary of Results from a Trial of a Novel Selective PPARɑ Modulator, Pemafibrate, on Lipid and Glucose Metabolism in Patients with Type 2 Diabetes and Hypertriglyceridemia1

By Kristen N Smith PhD RDN Mary R Dicklin PhD Kevin Maki PhD | Mar 5, 2018 | 0 Comments

Summary of Results from a Trial of a Novel Selective PPARɑ Modulator, Pemafibrate, on Lipid and Glucose Metabolism in Patients with Type 2 Diabetes and Hypertriglyceridemia By Kristen N Smith, PhD, RD, LD; Mary R Dicklin, PhD; Kevin C Maki, PhD  Background: Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of death in persons with…

Read More